IE 11 is not supported. For an optimal experience visit our site on another browser.

Ventrus Biosciences (VTUS) President, Chairman & CEO to Ring the NASDAQ Stock Market Closing Bell

ADVISORY, May 18, 2011 (GLOBE NEWSWIRE) --
/ Source: GlobeNewswire

ADVISORY, May 18, 2011 (GLOBE NEWSWIRE) --

What:

Ventrus Biosciences (VTUS), a specialty pharmaceutical company focusing in late-stage clinical development of gastrointestinal products, will visit the NASDAQ MarketSite in New York City's Times Square.  

In honor of the occasion, Russell Ellison, President, Chairman & CEO will ring the Closing Bell.

Where:

NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:

Thursday, May 19th, 2011 – 3:45 p.m. to 4:00 p.m. ET   

Contact:

David Barrett
646-706-5208
dbarrett@ventrusbio.com

NASDAQ MarketSite:
Jen Knapp
(212) 401-8916
Jennifer.knapp@nasdaqomx.com

Feed Information:

The entire Closing Bell is available from 3:50 p.m. to 4:05 p.m. on AMC-3/C-3 (dl 3760H). The feed can also be found on Ascent fiber 1623. Footage of the new logo unveiling will be available from 3:55 – 3:56 p.m. ET If you have any questions, please contact Jen Knapp (212) 401-8916.

Facebook and Twitter:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:

               

For news tweets, please visit our Twitter page at:

Webcast:

A live webcast of the NASDAQ Closing Bell will be available at:
or .

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to and click on the market close of your choice.

About Ventrus Biosciences (VTUS):

Ventrus is a development stage specialty pharmaceutical company focused on the development of late-stage prescription drugs for gastrointestinal disorders. Our lead product is Iferanserin (VEN 309) for the topical treatment of hemorrhoids. Our additional product candidate portfolio consists of two in-licensed late-stage drugs intended to treat anal fissures (VEN 307) and fecal incontinence (VEN 308). The first Phase III clinical trial with VEN 307 has begun in Europe and we expect data to be available in the second quarter of 2012. These candidates are two molecules that were previously approved and marketed for other indications and that have been formulated into our proprietary topical treatments for these new gastrointestinal indications.

About NASDAQ OMX:

The NASDAQ OMX Group, Inc. is the world's largest exchange company. It delivers trading, exchange technology and public company services across six continents, with more than 3,500 listed companies. NASDAQ OMX offers multiple capital raising solutions to companies around the globe, including its U.S. listings market, NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX first North, and the U.S. 144A sector. The company offers trading across multiple asset classes including equities, derivatives, debt, commodities, structured products and exchange-traded funds. NASDAQ OMX technology supports the operations of over 70 exchanges, clearing organizations and central securities depositories in more than 50 countries. NASDAQ OMX Nordic and NASDAQ OMX Baltic are not legal entities but describe the common offering from NASDAQ OMX exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For more information about NASDAQ OMX, visit . *Please follow NASDAQ OMX on Facebook () and Twitter (). 

NDAQA